Introduction
Esophageal cancer (EC) ranks as the eighth most common cancer and is the sixth most common cause of death from cancer worldwide. 1 Esophageal squamous cell carcinoma (ESCC), usually prevalent in Asia, accounts for about 90% of cases of EC.
2,3 TNM staging is widely used as predictive models for prognosis in ESCC. 4 However, the prognosis is usually very heterogeneous and unpredictable even in ESCC patients with same stage or similar pathologic features. It would be of great value to identify useful complementary biomarkers to stratify ESCC patients with high risk and to improve individualized treatment.
Data extraction
Two investigators (Sun and Zhang) independently reviewed the eligible studies and extracted the following data: surname of the first author, publication year, country, ethnicity, sample size, disease stage, histology type, cutoff value, and the outcomes. All data were then examined by the two investigators independently (Sun and Zhang). Disagreements were resolved by discussion.
Quality assessment
The quality of the methodology of the included studies was assessed by the Newcastle-Ottawa scale (NOS) recommended by the Cochrane Non-Randomized Studies Methods Working Group. 7 Studies with five or more stars were defined as high quality studies. Quality assessment was performed by two investigators (Sun and Zhang) independently. Disagreements were resolved by discussion.
statistical analysis
The relationship between NLR/PLR/LMR and OS/CSS or EFS was measured by the combined HRs and their 95% CIs extracted from each eligible study. The HR and its 95% CI in each eligible study were directly extracted from the report, or indirectly estimated by methods described by Tierney et al. 8 The combined HRs were estimated graphically by forest plots. ORs and their 95% CIs were combined to estimate the relationship between NLR/PLR/LMR and clinicopathological parameters. The overall HR/OR and its 95% CI overlap 1 were considered statistically significant and indicated a worse effect for the group with high NLR/PLR/LMR. Heterogeneity between studies was detected by the Q test and the I 2 metric (no heterogeneity: I 2 =0%-25%; moderate heterogeneity: 25%-50%; large heterogeneity: 50%-75%; and extreme heterogeneity: 75%-100%). 9 If P≥0.10 in the Q test or I 2 <50%, the fixed effect model (Mantel-Haenszel method) was used. 10 Otherwise, random effect model analysis was conducted. 11 Subgroup analysis by different analytical methods (cutoff value, sample size, treatment, and geographic region) was performed in the analysis of OS/CSS or EFS. In addition, publication bias was assessed by the method reported by Begg and Egger. 12, 13 All P-values were two-tailed and a P-value <0.05 was considered statistically significant. Most of the statistical analyses in this study were conducted using the STATA software (version 11.2; StataCorp LP, College Station, TX, USA). abstracts, 77 studies were excluded because they obviously did not meet our selection criteria. The remaining 55 studies were further examined. After carefully reading the full articles, 29 studies were excluded: four meta-analysis studies, one letter, 12 studies that included adenocarcinoma or other subtypes of EC, two studies that did not provide outcomes of interest, two studies that did not provide the cutoff value of NLR/PLR/ LMR, and eight studies with overlapping data. Finally, 26 studies including 8,586 ESCC patients were available for further analysis ( Figure 1 ). Among these, 23 studies reported NLR, 14, 15, [17] [18] [19] [20] [21] [22] [23] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] 12 studies reported PLR, 15, [18] [19] [20] 22, 26, 27, [32] [33] [34] 36, 39 and LMR was reported by six studies. 16, 20, 22, [24] [25] [26] All the included studies were carried out in Asia (15 studies in China, 10 studies in Japan, and only one study in Korea). The sample size of 16 studies was >200, 14, 15, 17, 18, 20, 22, [24] [25] [26] [29] [30] [31] [32] [33] [34] 37 and the remaining 10 studies involved <200 patients. 16, 19, 21, 23, 27, 28, 35, 36, 38, 39 Thirteen studies reported both survival and clinicopathological data, 15, 16, 20, [22] [23] [24] [25] [26] [31] [32] [33] [34] 37 and the other 13 studies only reported survival data. 14, [17] [18] [19] 21, [27] [28] [29] [30] 35, 36, 38, 39 Most studies 15, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 37 (n=19) involved surgery-based treatment, six 14, 16, 17, 35, 36, 38 used chemoradiotherapy (CRT), and one study involved both treatments. 39 The blood cell counts used to evaluate NLR/ PLR/LMR were obtained before treatment in all the included studies. The cutoff value of NLR in 23 studies ranged from 1.6 to 5; 13 studies 14, 15, 17, 19, 21, 27, 30, 31, 33, 35, 36, 38, 39 had a cutoff value ≥3, and the remaining 10 studies 18, 20, 22, 23, 26, 28, 29, 32, 34, 37 had a cutoff value <3. The cutoff value of PLR ranged from 103 to 244; five studies 15, 19, 26, 33, 39 had a cutoff value ≥150, and seven studies 18, 20, 22, 23, 27, 34, 36 had a cutoff value <150. Among the six studies that reported LMR, the cutoff value ranged from 2.57 to 4.02. LMR ≥3.5 was reported by three studies, 16, 20, 22 and the remaining three studies [24] [25] [26] reported LMR values <3.5. All included studies were scored high (with six stars or more). The baseline characteristics of the included studies are presented in Table 1 . Details of blood testing time, treatment methods, and NOS score are presented in Table S1 . (Table 3 ).
Results

literature search and study characteristics
The prognostic role of PlR in esCC
The relationship between PLR and OS/CSS was investigated by 12 studies. 15 Eight studies 15, 18, 20, 22, 26, [32] [33] [34] reported the relationship between PLR and clinicopathological parameters. We also found that high PLR was associated with depth of invasion (T3-T4 vs T1-T2: OR =1.49, 95% CI =1. 26 
The prognostic role of lMR in esCC
The impact of LMR on OS/CSS was evaluated by six studies, 16, 20, 22, [24] [25] [26] and three studies 16, 24, 26 Figure 4) .
The relationship between LMR and clinicopathological parameters was evaluated by six studies. 16, 20, 22, [24] [25] [26] Subgroup analysis was further conducted according to cutoff value (≥3 vs <3 for NLR, ≥150 vs <150 for PLR, and ≥3.5 vs <3.5 for LMR), sample size (≥200 vs <200), treatment (surgery-based vs CRT only), and geographic region (China vs non-China). The results of the subgroup analyses are presented in Table 2 . When the subgroup analysis was performed according to cutoff value, the HRs in studies with cutoff value ≥3 were 1.71 and 1.43 for OS/CSS and EFS, respectively, which were more significant than studies with cutoff value <3 (HRs were 1.41 and 1.26 for OS/CSS and EFS, respectively). This suggested that the higher the NLR, the worse the prognosis of the patient. Also, the heterogeneity in studies with cutoff value ≥3 (I 2 =40.1% and 0.0% for OS/CSS and EFS, respectively) was lower than studies with cutoff value <3 (I 2 =57.3% and 39.0% for OS/CSS and EFS, respectively). When the subgroup analysis was performed according to treatment (surgery-based vs CRT only) in OS/CSS, I
2 decreased in both subgroups (I 2 =45.7% and 37.0% for surgery-based and CRT only studies, respectively). Treatment methods might be the source of heterogeneity. Other subgroup analyses suggested a significant association between high NLR and poor OS/ CSS and EFS.
In studies exploring the prognostic role of PLR in ESCC, I
2 in the overall analysis was 33.1% (P=0.125) for OS/CSS. When the subgroup analysis was performed according to cutoff value, both studies with cutoff value ≥150 and <150 showed significant association. However, the heterogeneity in each group was reduced when compared with the overall analysis (I 2 =12.4%, P=0.36 for cutoff value ≥150; I 2 =26.0%, P=0.23 for cutoff value <150). This may suggest that different cutoff values of PLR maybe one of the sources of heterogeneity.
Low LMR was associated with poor OS/CSS in all subgroup analyses. The heterogeneity in studies with sample size ≥200 was moderate (I 2 =49.5%, P=0.114), and no heterogeneity was observed in studies with sample size <200 (I 2 =0.0%, P=0.70). As a result, the high heterogeneity (I 2 =64.0%, P=0.016) in the overall analysis might account for the subgroup analysis by sample size (≥200 and <200).
Publication bias
Begg's and Egger's tests were applied for publication bias detection. Only the analysis of the effect of LMR on OS/ CSS showed significant publication bias (P Begg =0.02, P Egger
=0.05
); other comparisons did not show any publication bias ( Table 2) .
Discussion
It is now generally recognized that inflammation response plays a critical role in tumor progression and may influence survival outcomes in patients with cancer. As systematic inflammatory markers, high neutrophil, platelet, and macrophage counts, low lymphocyte, and also high NLR, PLR, and low LMR have been recognized to be associated with unfavorable prognosis in solid tumors. In this meta-analysis, we comprehensively assessed the prognostic role of NLR, PLR, and LMR in ESCC by collecting the data set of 26 studies including 8,586 ESCC patients. We found that high NLR, PLR and low LMR were associated with poor survival and malignant phenotype such as deeper depth of invasion (T), positive lymph node metastasis (N), and advanced TNM stage. This preclinical and clinical research may lay the foundation for NLR, PLR, and LMR to serve as useful prognostic biomarkers and to stratify ESCC patients with high risk.
Previous meta-analyses have investigated the prognostic role of NLR and PLR in EC. Yang et al 40 first investigated the relationship between NLR and EC by summarizing six studies involving 1,633 patients with EC. Yodying et al analyzed seven studies including 1,540 EC patients to investigate the prognostic role of NLR and PLR in EC. 41 Huang et al 42 focused on the relationship between NLR and ESCC. Nine studies with 2,513 patients were included in their study. In a study by Zhao et al, 43 16 studies including 6,699 patients were utilized to investigate the prognostic role of PLR in EC patients. All these meta-analyses found that high NLR and PLR were associated with poor survival in EC. Our study showed the following advancements when compared with previous work. Firstly, our study was more comprehensive than earlier work. Prior to this, the prognostic role of NLR was mostly investigated by meta-analyses. One study evaluated both NLR and PLR; 41 PLR was investigated by one study. 43 The prognostic role of LMR had not been investigated yet. As NLR, PLR, and LMR were the mostly studied inflammatory biomarkers, for the first time we comprehensively investigated the prognostic role of the three inflammatory markers (NLR, PLR, and LMR) in ESCC. We found all these three markers to be associated with tumor progression and prognosis of ESCC patients. Secondly, the sample size in our analysis was larger than any previous metaanalysis. Twenty-six studies including 8,586 ESCC patients were available in our study, which was larger than the study by Yang et al 40 ESCC was a major type of EC (accounted for 90% of EC cases), we only focused on the prognostic role of NLR, PLR, and LMR on ESCC. This would reduce the potential bias induced by histology type. In a nutshell, our meta-analysis is more updated and comprehensive than previous works.
As ESCC is a complicated disease, many clinical variables or biomarkers are associated with the prognosis of ESCC, for example hemoglobin, CRP, squamous cell carcinoma antigen (SCC-Ag), fibrinogen, nutritional parameters, cell-free circulating tumor DNA, and circulating noncoding RNA. NLR, PLR, and LMR were just systemic inflammatory responserelated markers that affected the prognosis of ESCC. In some cases, these factors may even contradict each other. For example, all NLR, PLR and LMR are high, how to determine the prognosis of ESCC? As no studies have reported such a case, and available data are insufficient to analyze this situation, we failed to explore the result. However, to predict the prognosis of ESCC more accurately and usefully, we think it is better to combine these useful biomarkers together just as the Glasgow prognostic score, an inflammation-based score which combined albumin and C-reactive protein (CRP).
Some limitations should also be acknowledged. Firstly, the cutoff value of NLR/PLR/LMR varied in the included studies. The criteria and method used in different institutions to determine the cutoff value were different; we could not propose an appropriate cutoff value by statistical analysis. This may affect the results and induce unavoidable potential heterogeneity and bias. It may limit the usefulness of NLR/PLR/ LMR in clinical practice. Therefore, a standard and uniform cutoff value defining NLR/PLR/LMR is needed. Secondly, some factors such as age, sex, smoking history, tumor stage, comorbidities, and treatment method may affect the level of NLR/PLR/LMR, 44, 45 and also the prognosis in ESCC. However, we could not conduct a stratified analysis to assess the effects of confounding factors on the prognostic role of NLR/PLR/LMR in ESCC patients because of the limited information provided in the original studies. Lastly, publication bias was detected in the comparison of LMR in OS. Apart from this, potential publication biases may exist. Studies that failed to get published because of negative or null results could not be identified in our literature search and thus were not included in this analysis. In addition, some reports that did not provide sufficient data were also excluded from our analyses of the publications.
In conclusion, our analysis suggested high NLR, PLR and low LMR were associated with poor survival and malignant phenotype in ESCC patients. With the limitations, heterogeneities, and bias of meta-analysis, our conclusions in this study need to be interpreted with caution. Future large prospective studies with rigorously designed methodologies are warranted to confirm our results.
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